Lb Pharmaceuticals (LBRX) Non Operating Income (2024 - 2026)

Lb Pharmaceuticals' Non Operating Income history runs 3 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 171.59% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $8.3 million (changed N/A YoY), while the FY2025 annual figure was $5.2 million, up 200.75% from the prior year.
• Non Operating Income was $3.0 million for Q1 2026 at Lb Pharmaceuticals, up from $2.4 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $3.0 million in Q1 2026 to a low of $469000.0 in Q4 2024.
• Historically, Non Operating Income has averaged $1.8 million across 3 years, with a median of $1.8 million in 2024.
• Biggest YoY gain for Non Operating Income was 411.51% in 2025; the steepest drop was 11.15% in 2025.
• A 3-year view of Non Operating Income shows it stood at $469000.0 in 2024, then surged by 411.51% to $2.4 million in 2025, then gained by 27.14% to $3.0 million in 2026.
• The last three Non Operating Income figures came in at $3.0 million (Q1 2026), $2.4 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.